Trial Profile
An Open-label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between SAM-531 and Gemfibrozil, a Cytochrome P-450 2C8 Inhibitor, When Coadministered Orally to Healthy Young Adult Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cerlapirdine (Primary) ; Gemfibrozil (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Wyeth
- 02 Feb 2010 Actual patient number (17) added as reported by ClinicalTrials.gov.
- 02 Feb 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 02 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.